Agenus Reports Fourth Quarter and Full Year 2023 Results FDA Grants Fast Track designation for BOT/BAL in metastatic, refractory colorectal cancer (CRC) patients who have failed 1st and 2nd line standard of care treatments Data from Phase 1 of BOT/BAL in refractory CRC showed durable ORR of 24% in patients with non-active liver metastases (NLM); Completed enrollment of randomized Phase 2 trial (n=230) Clinical data sets path for expansion opportunities in pancreas, lung, neoadjuvant CRC, and melanoma LEXING ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA. In non-clinical assays, BMS-986442 demonstrated superior immune activation both as monotherapy and in combination with PD-(L)1 blockade compared to ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Nils Eckardt, Kent Barnes, and Brian Greenblatt, in connection with their appointments as Chief Medical Affairs Officer, Head of Marketing and Sales, and Vice President Commercial Operations and Business Analytics, respectively. The Compen ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Company will release its fourth quarter and year end 2023 financial results before the market opens on Thursday, March 14, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, plea ...

Three otherwise innocuous words -- reverse stock split -- can cause much disappointment and even sow panic in an investor community. Shareholders of clinical-stage biotech Agenus (AGEN -29.54%) experienced this vividly on Thursday when their company announced its intention to start going down that road. The stock's price fell sharply, by almost 30%, contrasting with the 0.6% gain of the benchmark S&P 500 index.Twenty shares will become oneIn a regulatory filing and a letter to its shareholders, both publish ...

Stay on the Internet long enough – and it won’t take too long, believe me – and you’ll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns to outright conspiracy theories, the suits on Wall Street don’t always get the love from retail investors. Plus, they tend to be conservative for good reason. You don’t want to destroy your reputation by endorsing junk securities.That said, we’re all human. And humans love every now and then to speculate – even th ...

After being mostly down over the past three years, the biotech sector rallied hard to end 2023. The SPDR S&P Biotech ETF (NYSEARCA:XBI) is up 31% in the last three months. From 2010 through 2019, investing in the XBI was a good proxy for the biotech sector. However, the monetary and regulatory landscape around biotech stocks continues to be challenging. Nevertheless, several biotech breakthroughs may allow the rally to continue, at least for certain individual stocks. As any biotech investor knows, you must ...

wildpixel Agenus Inc. (NASDAQ:AGEN), a pioneer in immunological cancer treatments, has recently unveiled impressive results from the NEST-1 study. This investigator-sponsored trial ("IST") focused on evaluating the combination of botensilimab and balstilimab ((BOT/BAL)) in the neoadjuvant setting for colorectal cancer (CRC). The data from the NEST-1 study present BOT/BAL as a potential game-changer in CRC treatment. The combination's ability to induce significant tumor regression and eliminate ctDNA ope ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in developing immunological cancer treatments, today announced results from the NEST-1 study, an investigator-sponsored trial (IST) evaluating the combination of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colorectal cancer (CRC), both those with Microsatellite Stable (MSS) CRC and Microsatellite Instability High (MSI-H) CRC. Dr. Pashtoon Kasi, M.D., Director of Colon Cancer Research at Weill-Cornell Medicine, ...

nopparit/iStock via Getty Images iTeos Therapeutics (NASDAQ:ITOS) is gearing up to report results from several of its programs in 2024. I believe that investors can benefit here, because there is potential with multiple shots on goal. Especially, with respect to the fact that there are two protein targets which have been validated to do well in targeting patients with cancers. Having said that, this company's pipeline is not solely only built around the targeting of TIGIT protein with Belrestotug [EOS-448] ...